October Research Highlights
Cedars-SinaiA Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
A Roundup of the Latest Medical Discoveries and Faculty News at Cedars-Sinai
A Rutgers expert provides guidance to those who might be at increased risk during pregnancy
Children aged 8 years or younger should be considered a group at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal, the official journal of The European Society for Pediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Keeping your child safe and healthy is a multifaceted priority for families, starting with the ride home from the hospital in a properly installed car seat.
A Yale-designed nasal vaccine can help bolster immune responses to COVID-19 in previously vaccinated animals and reduce viral transmission, Yale researchers report Oct. 27 in the journal Science.
UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.
New research led by researchers at the University of Miami Miller School of Medicine and published in the Journal of Hepatology, suggests that getting a third dose of the COVID-19 mRNA vaccine could overcome the decreased vaccine respons in cirrhosis patients and offer strong protection against the virus, severe illness, and death from COVID-19.
The LJI team plans to use their new map of the Lassa virus surface glycoprotein to design a much-needed vaccine.
A new study from the Centers for Disease Control and Prevention’s VISION Network presents and analyzes some of the first real-world data on mRNA COVID vaccine effectiveness during Omicron BA.4 and BA.5 predominance for immunocompromised adults.
The Global Virus Network (GVN), representing 68 Centers of Excellence and 11 Affiliates in 39 countries comprising foremost experts in every class of virus causing disease in humans, and the Mahidol University in Thailand announced the addition of the Mahidol Virus Network as GVN’s newest Center of Excellence.
A subset of healthcare workers vaccinated against COVID-19 had unexpectedly low responses to the immunizations, according to Cedars-Sinai investigators. The findings of the new study are published in iScience, a Cell Press journal.
Cash transfers had limited outcomes for increasing vaccination efforts among adults, according to research led by Columbia University Mailman School of Public Health and the University of the Witwatersrand, Johannesburg (Wits).
Researchers at the University of Illinois College of Veterinary Medicine have demonstrated in a mouse model that a specific type of T cell, one of the body’s potent immune defenses, produces cytokines that are necessary for the body to acquire immunity against fungal pathogens.
Cedars-Sinai and other hospitals nationwide are seeing a surge in cases of pediatric RSV (respiratory syncytial virus) that are showing up earlier than expected this year. Healthcare providers are worried about the onset of the virus combined with the additional threats of the flu and COVID-19 as we head into winter.
Individuals who deal with anxiety are no less hesitant to get the COVID-19 vaccine compared to those without anxiety, according to new research.
New research on COVID-19 vaccine hesitancy in Black, Latinx communities could help shape more persuasive messages to boost uptake.
Preclinical studies in mice that model human COVID-19 suggest that an inexpensive, readily available amino acid might limit the effects of the disease and provide a new off-the-shelf therapeutic option for infections with SARS-CoV-2 variants and perhaps future novel coronaviruses.
A lecturer and his research team from Faculty of Veterinary Science, Chulalongkorn University, have developed “FLAVO INNOVAC” nanovaccine for the prevention of bacterial gills diseases in freshwater fish species such as Tilapia and freshwater Asian sea bass. This nanovaccine is an effective solution that reduces the risk of death from diseases and the limitations of vaccine injections.
The latest articles that have been added to the Environmental Health channel.
Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery in this trial that enrolled more than 1,500 participants in the United States.
Drucilla J. Roberts, MD, from the Mass General Department of Pathology and colleagues recently published a literature review in the American Journal of Obstetrics & Gynecology, titled SARS-CoV-2 Placentitis, Stillbirth and Maternal COVID-19 Vaccination: Clinical-Pathological Correlations.
Pfizer didn’t claim to have tested its COVID-19 vaccine’s ability to prevent transmission, and this information was clearly available in press releases published by the European Medicines Agency as well as the published study containing results from Pfizer’s clinical trials.
People who have received two or three doses of an mRNA COVID-19 vaccine are significantly more likely to have milder illnesses if infected with the Delta or Omicron coronavirus variants than those who are unvaccinated, according to a nationwide study involving a team of University of Utah researchers.
The GW School of Medicine and Health Sciences is recruiting participants for the final stage of a clinical trial to evaluate two Omicron-specific vaccines. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The George Washington University School of Medicine and Health Sciences has received funding support as an agreement under NIH contract number 75N91019D00024 to Leidos Biomedical Research in Frederick, Maryland.
The study of individuals from six countries finds that Europeans support transferring COVID-19 vaccines to poorer nations and prioritising those with the greatest need regardless of their country of residence.
The symptoms reported after administration of the Pfizer-BioNTech COVID-19 vaccine were comparable overall to those for approved non–SARS-CoV-2 vaccines in this study including 7,800 children younger than age 5.
A vaccine that could protect against new variants of SARS-CoV-2 and also potentially protect against other coronaviruses is one step closer to reality thanks to College of Medicine researchers.
FAU researchers and collaborators provide the most updated guidance to health care providers and urge how widespread vaccination with these boosters can now avoid the specter of future and more lethal variants becoming a reality.
Five experts from the Perelman School of Medicine at the University of Pennsylvania have been elected to the National Academy of Medicine (NAM), one of the nation’s highest honors in the fields of health and medicine. Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman are among the 100 new members, elected by current NAM members.
New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.
People with HIV who have moderate immune suppression appear to be at greater risk of severe COVID-19 “breakthrough” infection after vaccination, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
It’s that time of year: costumes, candy and trick-or-treating. As families celebrate this season, Johns Hopkins Children’s Center experts are available for interviews on a variety of tips to help ensure a safe and fun Halloween.
Rutgers New Jersey Medical School is one of nearly 80 sites in the United States that will enroll participants in a new study to evaluate whether tecovirimat is effective in treating human monkeypox.
People living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline, say experts on an international panel convened last year to address gaps in the current TB vaccine landscape. Their recommendations appear in a new paper published today in The Lancet HIV.
Flu season is here. Rutgers Cancer Institute expert shares what cancer patients and their families need to know.
“Smart surveillance” for viral spillover from animals to humans, targeted preparedness & drug/vaccine research, & worldwide cooperation on stopping disease spread are required to reduce deaths & lessen economic consequences of the next pandemic, according to an international team of scientists.
University of Maryland School of Medicine researchers have identified how multiple genes of SARS-CoV-2 affect disease severity, which could lead to new ways in how we develop future vaccines or develop newer treatments. The genes control the immune system of the host, contributing to how fiercely the body responds to a COVID-19 infection.
A meta-analysis of 32 studies showed that the immune system within the vagina ebbs and flows, depending on menstrual-cycle stage. The analysis identified 53 distinct messages that immune cells sent to one another.
Referrals to Cambridge’s long COVID clinic fell dramatically in the period August 2021 to June 2022, which researchers say is likely due to the successful rollout of the vaccine.
One year after mass vaccination against COVID-19 was launched, inactivated virus vaccines accounted for half of the doses administered worldwide.
The coronavirus 2019 disease (COVID-19) pandemic has affected millions worldwide and claimed multiple lives. The elderly—aged above 60 years—remain the most vulnerable group.
The complex, multiple factors influencing COVID-19 vaccine hesitancy and scepticism among UK South Asian communities mean ‘quick fix’ solutions to increase uptake of the vaccines will be ineffective, according to new research published by JRSM Open.
An international team of researchers has demonstrated that among patients hospitalized for influenza, those who were vaccinated had less severe infections, including reducing the odds for children requiring admittance to an intensive care unit by almost half.
As COVID-19 wreaks havoc across the globe, one characteristic of the infection has not gone unnoticed. The disease is heterogeneous in nature with symptoms and severity of the condition spanning a wide range.
In a new study published online ahead of print in the journal Vaccine, Moffitt Cancer Center researchers identify factors associated with high and low COVID-19 vaccine acceptance among cancer patients.
The National Institutes of Health has awarded Amelia Escolano, Ph.D., assistant professor in The Wistar Institute’s Vaccine & Immunotherapy Center, the 2022 NIH Director’s New Innovator Award.
In one of the largest single-center COVID-19 cohort studies to date, researchers at the Icahn School of Medicine at Mount Sinai, using samples collected during the peak of the pandemic in New York City, have identified a key driver of COVID-19 disease severity.
In this population-based surveillance, the authors found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200,000 doses after the first dose and 1 in 30,000 doses after second dose of the primary series, and 1 in 50,000 doses after the first booster. The incidence varied markedly by age and sex, however, with a disproportionate number of cases occurring in male persons, notably among adolescents after dose 2 and first boosters.